Eye drops Brimonal are shown:
Active ingredient: 1 ml of brimonidine tartrate - 2 mg;
1 ml contains 23 drops;
Excipients: sodium chloride, tartaric acid, sodium tartrate, hypromellose, benzalkonium chloride, sodium hydroxide, water for injection.
Hypersensitivity to the active substance or other components of the preparation.
Simultaneous use with MAO inhibitors and antidepressants that affect noradrenergic transmission (for example, tricyclic and tetracyclic antidepressants, mianserin).
Children's age (up to 18 years old).
Breastfeeding period.
The preparation is prescribed for adults.
It is recommended to instill one drop of Brimonal 0.2% into the affected eye twice a day with an interval of 12 hours.
No dose adjustment is required for the elderly.
As with any eye drops, it is recommended to press for one minute on the area of the lacrimal sac in the inner corner of the eye to reduce systemic absorption. This should be done immediately after each drop is instilled. If more than one type of eye drops is prescribed, they should be instilled with an interval of 5-15 minutes.
Pregnant
Contraindicated.
Children
Contraindicated.
Drivers
Brimonidine can cause dizziness, drowsiness, blurred vision, which may affect the ability to drive vehicles and mechanisms. Such activities can be started no earlier than 15 minutes after applying the drops, until the vision clears up.
With oral overdose of other alpha-2-agonists, cases of such symptoms have been reported: arterial hypotension, asthenia, vomiting, lethargy, sedation, bradycardia, arrhythmia, miosis, apnea, hypothermia, respiratory depression and convulsions.
Treatment is symptomatic.
On the part of the organs of vision. Very common: eye irritation (redness of the eye, burning and tingling sensation, foreign body sensation, conjunctival follicles, itchy eyes), blurred vision, allergic blepharitis, allergic blepharoconjunctivitis, allergic conjunctivitis, allergic eye reactions and follicular conjunctivitis.
Simultaneous use with MAO inhibitors and antidepressants that affect noradrenergic transmission (for example, tricyclic and tetracyclic antidepressants, mianserin) is contraindicated.
Although the specific interaction of brimonidine with preparations has not been studied, one should take into account the possibility of an additive or enhancing effect of the preparation on the action of preparations that depress the central nervous system (alcohol, barbiturates, opiates, sedatives and anesthetics).
Keep out of the reach of children, protected from light at a temperature not exceeding 25 ° C. Do not freeze.
Store no more than 28 days after opening.
Shelf life is 2 years.
There are no reviews for this product.